{"organizations": [], "uuid": "8d5a2e414eb681ee1605f8c8eee95f53f58b23ca", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/16/globe-newswire-ascendis-pharma-as-announces-year-end-2017-financial-results-and-business-updateaconference-call-on-march-28.html", "country": "US", "domain_rank": 767, "title": "Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.806, "site_type": "news", "published": "2018-03-16T14:00:00.000+02:00", "replies_count": 0, "uuid": "8d5a2e414eb681ee1605f8c8eee95f53f58b23ca"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/16/globe-newswire-ascendis-pharma-as-announces-year-end-2017-financial-results-and-business-updateaconference-call-on-march-28.html", "ord_in_thread": 0, "title": "Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28", "locations": [], "entities": {"persons": [], "locations": [{"name": "copenhagen", "sentiment": "none"}, {"name": "denmark", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "ascendis pharma a/s", "sentiment": "negative"}, {"name": "ascendis pharma", "sentiment": "none"}, {"name": "ascendis pharma a/s ascendis pharma", "sentiment": "none"}, {"name": "transcon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "COPENHAGEN, Denmark, March 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will hold a conference call and live webcast on Wednesday, March 28, 2018 at 4:30 p.m. Eastern Time (ET) to review its 2017 financial results and provide a business update.\nConference Call Details\nDate Wednesday, March 28, 2018 Time 4:30 p.m. ET Dial In (U.S.) 844-290-3904 Dial In (International) 574-990-1036 Access Code 6799954 A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com . A webcast replay will be available on this website shortly after conclusion of the event for 30 days.\nAbout Ascendis Pharma A/S\nAscendis Pharma is applying its innovative prodrug technology to build a leading, fully integrated rare disease company focused on making a meaningful difference in patientsâ€™ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience.\nAscendis Pharma has a wholly-owned pipeline of three rare disease endocrinology programs, including once-weekly TransCon Growth Hormone, which is currently being evaluated in a phase 3 program for children with growth hormone deficiency (GHD), TransCon PTH, a long-acting prodrug of parathyroid hormone for hypoparathyroidism currently in a phase 1 trial, and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide for achondroplasia. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology.\nFor more information, please visit www.ascendispharma.com .\nForward-Looking Statements\nThis press release contains that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are . Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply our prodrug technology to build a leading, fully integrated rare disease company, (ii) our expectations regarding our ability to create therapies with potential for best-in-class efficacy, safety and/or convenience and (iii) our product pipeline. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the and you should not place undue reliance on these . Actual results or events could the plans, intentions, expectations and projections disclosed in the . Various important factors could cause actual results or events to the that we make, including the following: unforeseen safety or efficacy results in our TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these , as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F for the year ended December 31, 2016, which we filed with the SEC on March 22, 2017. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any , except as required by law.\nInternal contact: Scott T. Smith Chief Financial Officer (650) 352-8389 ir@ascendispharma.com Investor contact: Patti Bank Westwicke Partners (415) 513-1284 patti.bank@westwicke.com Media contact: Ami Knoefler SparkBioComm (650) 739-9952 ami@sparkbiocomm.com\nSource:Ascendis Pharma A/S", "external_links": ["https://www.globenewswire.com/Tracker?data=frNY2WAvTUPViBJiro1DZCz21A5JWC4fPVjAa7wo_SLr_EefaDSICUwYkwnB4pUlzpPgTZ9BUPi8ZmTdyAMHUAQ_0f70lEIb-QB_gMuRtw8=", "https://www.globenewswire.com/Tracker?data=frNY2WAvTUPViBJiro1DZCz21A5JWC4fPVjAa7wo_SKbniw8MminCZadnuDKBPd-B_yG5SaWoLdZQ9O_VvAFjoQJfBTseKuU85WeJ5XBOcU=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/b4b7c29a-478e-4a8e-b23b-b6a1cb18aee8"], "published": "2018-03-16T14:00:00.000+02:00", "crawled": "2018-03-16T15:14:56.014+02:00", "highlightTitle": ""}